Phathom Pharmaceuticals announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day. Although Erosive GERD is a highly symptomatic condition that can have a detrimental impact on millions of patients, there has been little medical innovation in this category in decades, until now,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals. “We believe our new DTC campaign is accessible, memorable, and informative. Our goal is to connect with people unsatisfied with their current treatment options and empower them to explore the power of VOQUEZNA with their healthcare provider.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
- Siga Technologies appoints Larry Miller as general counsel
- Short Report: Bearish positions reduced after contrasting C3.ai and Figs results
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Phathom Pharmaceuticals reports Q4 EPS ($1.39), consensus ($1.08)
Questions or Comments about the article? Write to editor@tipranks.com